Small Molecules
20 December 2024
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy19 December 2024
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical19 December 2024
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist19 December 2024
FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)17 December 2024
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer14 December 2024
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)11 December 2024
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial11 December 2024
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition11 December 2024
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy11 December 2024
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU4 December 2024
Evommune Presents Positive Clinical Results of its MRGPRX2 Antagonist (EVO756) at the 7th GA²LEN Global Urticaria Forum4 December 2024
First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO GuidelinesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports